Medidata Teams Up With Mundipharma Research to Move Clinical Research to the Cloud

NEW YORK, N.Y. – November 5, 2014 – Medidata (NASDAQ: MDSO), the leading global provider of cloud-based technology for clinical research in life sciences, recently announced that Mundipharma Research Limited (Mundipharma) has adopted Medidata’s cloud-based software platform to streamline and accelerate its drug development activities. As part of this agreement, Mundipharma will use the Medidata Clinical Cloud^® software platform to capture clinical research data electronically and leverage the platform’s analytics tools to enhance the speed and safety of its clinical trials.

Based in Cambridge, UK and Limburg, Germany, Mundipharma develops partnerships with a wide range of pharmaceutical and biotech companies to bring medications to an international market. Working on behalf of their independent associated companies and in collaboration with pharmaceutical companies, Mundipharma focuses on three main therapeutic areas—pain, oncology and respiratory diseases—carrying out early and late-stage pre-commercial development.

“We’re pleased to be working with Medidata to move our clinical trials from paper to the cloud,” said Terry Nichols, director of clinical research operations at Mundipharma. “The key for us is adopting technologies and ways of working that improve efficiency and promotes quality. Using Medidata’s cloud-based software solutions, we can capture clinical data electronically and access that data via a single web sign-on so that the hundreds—even thousands—of doctors and physicians involved in our clinical trials can access the same data in real time, working collaboratively.”

In addition to adopting Medidata’s cloud-based technology for electronic data capture and management (EDC), Mundipharma will also implement safety data transmission, medical coding and clinical business analytics modules that form part of the Medidata Clinical Cloud software platform. These tools aim to streamline clinical trial processes, foster collaboration between data management and safety management teams, and highlight clinical trial performance across organizations and against industry benchmarks. As an active member of the Clinical Data Interchange Standards Consortium (CDISC) and other standards bodies, Medidata continues to work to ensure these and future features of its cloud-based technology platform meet industry standards and interoperability requirements.

“By its nature, clinical research is a collaborative undertaking among developers, clinicians and patients, and better technology and data can drive better clinical decisions,” said Glen de Vries, president of Medidata. “We’re thrilled to work with Mundipharma to introduce transformational technologies that drive more informed R&D decisions.”

Connect with Medidata:

• Read our blog, Geeks Talk Clinical

• Tweet this: .@Medidata teams up with Mundipharma Research to move #clinical research to the cloud http://bit.ly/1zu9jLR

• Follow us on Twitter: @Medidata

• Find us on LinkedIn

  About Mundipharma Research
  Mundipharma Research is a young, dynamic organization wholly dedicated to the research and development of highly effective and innovative medications. Based in Europe (in Cambridge, England, and Limburg, Germany), we work on behalf of our independent associated companies and in collaboration with pharmaceutical companies to bring medications to both the European and the global market. For more information please visit: www.mundipharma-rd.eu

  About Medidata Solutions
  Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud^® brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

  Investor Contact: Hulus Alpay, Medidata Solutions, 212-419-1025, halpay@mdsol.com
  Media Contact – Americas: Nicole Pariser, Medidata Solutions, 212-659-1069,
  npariser@mdsol.com
  Media Contact – EMEA: Jayson Otke, Medidata Solutions, +44(0) 7930 104480,
  jotke@mdsol.com